Ondine Biomedical Inc. Notice of AGM (2546Y)
May 03 2023 - 2:02AM
UK Regulatory
TIDMOBI
RNS Number : 2546Y
Ondine Biomedical Inc.
03 May 2023
3 May 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Notice of AGM
Ondine Biomedical Inc. (AIM: OBI) announces that the notice of
the Company's 2023 Annual General Meeting ("AGM") and the
associated form of proxy have been published today on the Company's
website at https://ondinebio.com/investors/reports-documentation/
.
Printed copies of the notice of AGM and form of proxy will be
posted today to registered shareholders who have elected to receive
paper communications.
The Company's AGM will be held virtually at 8:00 a.m. (Pacific
time) on 24 May 2023. Details of how to access the meeting are
contained in the notice of AGM.
All shareholders are encouraged to submit their vote by proxy,
well in advance of the meeting. Details of how to vote by proxy are
contained in the notice of AGM. All valid proxy votes (whether
submitted electronically or in hard copy form) will be included in
the poll vote to be taken at the meeting.
The result of the AGM will be announced after its conclusion and
published on the Company's website.
A separate release will be made relating to the announcement of
Ondine's full year results to 31 December 2022 and the expected
publication of the Company's Annual Report and Accounts.
**ENDS**
Ondine Biomedical Inc.
+001 (604)
Angelika Vance, Corporate Communications 838 2702
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0)20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0)77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered life sciences
company that is the leader in photodisinfection therapies. Ondine
has a pipeline of investigational products, based on its
proprietary photodisinfection platform, in various stages of
development. Products beyond nasal photodisinfection include
treatments for a variety of medical indications such as chronic
sinusitis, ventilator-associated pneumonia, burns, and other
indications.
About photodisinfection
Ondine's photodisinfection is a patented technology using a
proprietary photosensitizer (non-antibiotic, light-activated
solution) to destroy pathogens. When illuminated with a specific
wavelength of light, the photosensitizer is activated, causing an
oxidative burst that is lethal to all types of pathogens.
Ondine's nasal photodisinfection system has a CE mark and is
approved in Canada and several other countries under the name
Steriwave(TM). It has been used in Canada for over ten years, with
no serious adverse events reported. In the US, it is currently
undergoing clinical trials for regulatory approval.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAAJMRTMTMMMTJ
(END) Dow Jones Newswires
May 03, 2023 03:02 ET (07:02 GMT)
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From Apr 2024 to May 2024
Ondine Biomedical (LSE:OBI)
Historical Stock Chart
From May 2023 to May 2024